Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Lyra Therapeutics (LYRA) over the last 2 years, with Q4 2024 value amounting to $17000.0.

  • Lyra Therapeutics' Asset Writedowns and Impairment rose 11250.0% to $17000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $17000.0, marking a year-over-year decrease of 9910.1%. This contributed to the annual value of $1.9 million for FY2024, which is 1875.0% up from last year.
  • As of Q4 2024, Lyra Therapeutics' Asset Writedowns and Impairment stood at $17000.0, which was up 11250.0% from $1.9 million recorded in Q2 2024.
  • Lyra Therapeutics' 5-year Asset Writedowns and Impairment high stood at $1.9 million for Q2 2024, and its period low was $8000.0 during Q4 2023.